This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics

SAVINGS DEADLINE EXPIRES IN:

  • 00
    Days
  • 00
    Hrs
  • 00
    Mins
  • 00
    Secs
May 14-17, 2024 | In-Person + Digital
Boston, MA, USAHynes Convention Center

JenKem Technology

Profile

“Founded in 2001, JenKem Technology specializes in commercial manufacture, research, development, and custom synthesis, of high-quality polyethylene glycol (PEG) derivatives, PEG co-polymers, and monodisperse PEGs.

JenKem Technology supplies high quality PEG derivatives worldwide, from R&D through GMP commercial quantities, for preclinical studies, clinical trials, and commercial products for pharma, biotech, medical devices, and diagnostics.

Additionally, JenKem Technology offers PEGylation services for oligonucleotides, peptides, proteins, and small molecules, up to preclinical stage. JenKem Technology can coordinate the IND enabling preclinical study data for PEGylated compounds together with partner CROs, to determine the optimal PEGylated compounds for customers’ application.

Please contact us at sales@jenkemusa.com or visit our website https://www.jenkemusa.com for more information about our PEG products and PEGylation services.”